OBJECTIVE: Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), followed by stereotactic body radiotherapy (SBRT) with the radiosensitizer nelfinavir. MATERIALS AND METHODS: Following imaging, pathologic confirmation, and staging laparoscopy, subjects received three 3-week cycles of CIT (gemcitabine/leucovorin/fluorouracil/oregovomab). Thereafter, nelfinavir was delivered (1250 mg bid) for 5 weeks, with SBRT (40 Gy/5 fractions) occurring during the third week of nelfinavir. Following another cycle of CIT, pancreaticoduodenectomy was performed if resectable. Three more cycles of CIT were then delivered (total 7 cycles). In subjects with high (≥10 U/mL) CA-125, oregovomab (2 mg) was administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively). The enzyme-linked immunospot assay evaluated the development of CA-125-specific CD8 T-lymphocytes. RESULTS: The trial was prematurely closed because gemcitabine/leucovorin/fluorouracil was replaced by FOLFIRINOX and gemcitabine/nab-paclitaxel as the standard of care. Median follow-up was 13 months. Of 11 enrolled patients, 10 had high CA-125; 1 patient suffered an unexpected cardiac-related death, so 9 subjects received oregovomab. Ten received SBRT and 4 underwent resection. Overall, 6/11 patients experienced any grade ≥3 event. The median survival and time to progression were 13 and 8.6 months, respectively. Five patients had samples available for immunospot testing, of whom 2 (40%) developed CA-125-specific CD8 T-lymphocytes. CONCLUSION: A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity. Re-evaluation with modern systemic paradigms is recommended.
OBJECTIVE:Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer. This phase I/II trial (NCT01959672) evaluated the safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti-CA-125), followed by stereotactic body radiotherapy (SBRT) with the radiosensitizer nelfinavir. MATERIALS AND METHODS: Following imaging, pathologic confirmation, and staging laparoscopy, subjects received three 3-week cycles of CIT (gemcitabine/leucovorin/fluorouracil/oregovomab). Thereafter, nelfinavir was delivered (1250 mg bid) for 5 weeks, with SBRT (40 Gy/5 fractions) occurring during the third week of nelfinavir. Following another cycle of CIT, pancreaticoduodenectomy was performed if resectable. Three more cycles of CIT were then delivered (total 7 cycles). In subjects with high (≥10 U/mL) CA-125, oregovomab (2 mg) was administered for 7 total doses (3 pre-SBRT, 1 between SBRT and resection, and 3 postoperatively). The enzyme-linked immunospot assay evaluated the development of CA-125-specific CD8 T-lymphocytes. RESULTS: The trial was prematurely closed because gemcitabine/leucovorin/fluorouracil was replaced by FOLFIRINOX and gemcitabine/nab-paclitaxel as the standard of care. Median follow-up was 13 months. Of 11 enrolled patients, 10 had high CA-125; 1 patient suffered an unexpected cardiac-related death, so 9 subjects received oregovomab. Ten received SBRT and 4 underwent resection. Overall, 6/11 patients experienced any grade ≥3 event. The median survival and time to progression were 13 and 8.6 months, respectively. Five patients had samples available for immunospot testing, of whom 2 (40%) developed CA-125-specific CD8 T-lymphocytes. CONCLUSION: A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity. Re-evaluation with modern systemic paradigms is recommended.
Authors: T G Ehlen; P J Hoskins; D Miller; T L Whiteside; C F Nicodemus; B C Schultes; K D Swenerton Journal: Int J Gynecol Cancer Date: 2005 Nov-Dec Impact factor: 3.437
Authors: T A Sohn; C J Yeo; J L Cameron; L Koniaris; S Kaushal; R A Abrams; P K Sauter; J Coleman; R H Hruban; K D Lillemoe Journal: J Gastrointest Surg Date: 2000 Nov-Dec Impact factor: 3.452
Authors: Alan N Gordon; Birgit C Schultes; Holly Gallion; Robert Edwards; Theresa L Whiteside; Jennifer M Cermak; Christopher F Nicodemus Journal: Gynecol Oncol Date: 2004-08 Impact factor: 5.482
Authors: Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff Journal: PLoS Med Date: 2010-04-20 Impact factor: 11.069
Authors: Chandrajit P Raut; Douglas B Evans; Christopher H Crane; Peter W T Pisters; Robert A Wolff Journal: Surg Oncol Clin N Am Date: 2004-10 Impact factor: 3.495
Authors: Raffit Hassan; Charles Schweizer; Kun F Lu; Barbara Schuler; Alan T Remaley; Susan C Weil; Ira Pastan Journal: Lung Cancer Date: 2009-09-09 Impact factor: 5.705
Authors: Jean L Grem; Mary G Quinn; Bruce Keith; Brian P Monahan; J Michael Hamilton; Yan Xu; Nancy Harold; Dat Nguyen; Chris H Takimoto; Anthony Rowedder; Janet Pang; Geraldine Morrison; Alice Chen Journal: Cancer Chemother Pharmacol Date: 2003-08-29 Impact factor: 3.333
Authors: Patricia Braly; Christopher F Nicodemus; Christina Chu; Yvonne Collins; Robert Edwards; Alan Gordon; William McGuire; Christopher Schoonmaker; Theresa Whiteside; Lesley Mary Smith; Michael Method Journal: J Immunother Date: 2009-01 Impact factor: 4.456
Authors: Hakm Y Murad; Partha K Chandra; Charles A Kelly; Namrata Khurana; Heng Yu; Emma P Bortz; Shirley N Hong; Debasis Mondal; Damir B Khismatullin Journal: Antioxidants (Basel) Date: 2022-02-09
Authors: Maximilian N Kinzler; Falko Schulze; Steffen Gretser; Nada Abedin; Jörg Trojan; Stefan Zeuzem; Andreas A Schnitzbauer; Dirk Walter; Peter J Wild; Katrin Bankov Journal: Cancers (Basel) Date: 2022-09-27 Impact factor: 6.575
Authors: Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Martijn R Meijerink; Hester J Scheffer Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639
Authors: Vida Mashayekhi; Orsola Mocellin; Marcel H A M Fens; Gerard C Krijger; Lodewijk A A Brosens; Sabrina Oliveira Journal: Theranostics Date: 2021-08-25 Impact factor: 11.556